Sanofi SA’s decision to acquire the US synthetic biology company Synthorx Inc gives the French multinational new tools for expanding its oncology portfolio. Sanofi announced the takeover on 9 December, just a day before its new chief executive, Paul Hudson, briefed investors on the company’s R&D strategy going forward. This will focus on rare diseases, immunology and oncology, while discontinuing research in diabetes and cardiovascular medicine.
